Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Pharma
In 3rd bankruptcy bid, J&J sweetens talc settlement offer to $8B
With the bankruptcy maneuver, J&J is attempting to wash its hands of lawsuits claiming the company’s talc products caused users to develop cancer.
Fraiser Kansteiner
Sep 23, 2024 9:33am
Oregon judge sides with J&J, overturning $260M talc verdict
Sep 17, 2024 8:17am
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Sep 14, 2024 8:45am
Verastem sets first awareness day for rare ovarian cancer
Sep 3, 2024 3:20pm
J&J proposes $505M settlement with bankrupt talc miners
Jul 16, 2024 8:10am
AbbVie's ImmunoGen buyout bears fruit with midstage trial win
Jun 6, 2024 11:22am
